Last quarter (Q3 2023), MustGrow Biologics's total revenue was C$―, a decrease of ― from the same quarter last year. In Q3, MustGrow Biologics's net income was C$-1.86M. See MustGrow Biologics’s key income statements, including revenue, expenses, profit, and income.

Income Statement	TTM	Dec 22	Dec 21	Dec 20	Dec 19	Dec 18
Total Revenue	-	C$ 6.48K	C$ 12.87K	C$ 0.00	C$ 0.00	C$ 2.00K
Cost of Revenue	-	-	-	-	-	-
Gross Profit	-	C$ 6.48K	-	-	-	-
Operating Expense	C$ 5.36M	C$ 5.69M	C$ 3.02M	C$ 3.37M	C$ 1.47M	C$ 1.86M
Operating Income	C$ -5.36M	C$ -5.69M	C$ -3.01M	C$ -3.37M	C$ -1.47M	C$ -1.85M
Net Non Operating Interest Income Expense	C$ 232.67K	C$ 93.48K	C$ 52.77K	C$ -45.87K	C$ -45.88K	C$ -40.24K
Other Income Expense	-	-	-	C$ 105.19K	-	-
Pretax Income	C$ -5.11M	C$ -5.57M	C$ -3.06M	C$ -3.31M	C$ -1.52M	C$ -1.89M
Tax Provision	-	-	-	-	-	-
Earnings From Equity Interest Net Of Tax	-	-	-	-	-	-
Net Income Common Stockholders	C$ -5.11M	C$ -5.57M	C$ -3.06M	C$ -3.31M	C$ -1.52M	C$ -1.89M
Basic EPS	C$ -0.10	C$ -0.11	C$ -0.07	C$ -0.09	C$ -0.06	C$ -0.08
Diluted EPS	C$ -0.10	C$ -0.11	C$ -0.07	C$ -0.09	C$ -0.06	C$ -0.08
Basic Average Shares	C$ 198.27M	C$ 49.01M	C$ 43.74M	C$ 37.31M	C$ 25.29M	C$ 24.99M
Diluted Average Shares	C$ 198.27M	C$ 49.01M	C$ 43.74M	C$ 37.31M	C$ 25.29M	C$ 24.99M
Dividend Per Share	-	-	-	-	-	-
Total Operating Income As Reported	-	-	-	-	-	-
Reported Normalized Basic E P S	-	-	-	-	-	-
Reported Normalized Diluted E P S	-	-	-	-	-	-
Rent Expense Supplemental	-	-	-	-	-	-
Total Expenses	C$ 5.36M	C$ 5.69M	C$ -3.02M	C$ 3.37M	C$ 1.47M	C$ 1.86M
Net Income From Continuing And Discontinued Operation	C$ -5.11M	C$ -5.57M	C$ -3.06M	C$ -3.31M	C$ -1.52M	C$ -1.89M
Normalized Income	C$ -3.76M	C$ -4.09M	C$ -2.25M	C$ -3.42M	C$ -1.52M	C$ -1.89M
Interest Expense	-	-	-	C$ 45.87K	C$ 45.88K	C$ 40.24K
EBIT	C$ -5.11M	C$ -5.56M	C$ -3.01M	C$ -3.26M	C$ -1.47M	C$ -1.85M
EBITDA	C$ -5.11M	C$ -5.56M	C$ -3.01M	C$ -3.26M	C$ -1.47M	C$ -1.85M

Currency in CAD

MustGrow Biologics Earnings and Revenue History

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing